# Luma Group

> Luma Group is a VC fund in New York backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 5
- Last investment: Apr 2026
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/luma-group-investment-firm
- Website: https://www.lumagroup.com

Luma Group is an investment firm focused on the intersection of technology-driven life sciences and healthcare companies.

## Contacts

5 contacts available for Luma Group. Shizune tracks 1 team members at Luma Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/luma-group-1729?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $40M–$125M |
| Series B | $55M–$93M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Health Care | 3 | 60% |
| Biopharma | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| Analytics | 1 | 20% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 60% |
| Belgium | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Themasap Khan | Co-Founder and Partner | 2 | https://shizune.co/investors/profile/themasap-khan |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Coultreon Biopharma | Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M | Series A | Apr 28, 2026 |  |
| Aeovian Pharmaceuticals | Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $55M | Series B | Dec 16, 2025 |  |
| Curve Biosciences | Curve Biosciences is a biotechnology company focused on enhancing chronic disease care through precision medicine. With a team led by experts such as Nathan Hunkapiller, PhD, as Chief Scientific Officer, and Chuba Oyolu, PhD, as Chief Technology Officer, the company is at the forefront of research and development in the biotech field. CurveBiosciences aims to leverage scientific advancements to provide targeted solutions for chronic diseases, emphasizing the importance of precision in treatment approaches. The company operates within the biotechnology industry and is dedicated to improving patient outcomes through innovative research. | $40M | Series A | Oct 29, 2025 |  |
| Character Biosciences | Biopharmaceutical research and development company that's an affiliate of Clover Health | $93M | Series B | Mar 25, 2025 |  |
| ArsenalBio | ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughputtarget identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. | $325M | Series C | Sep 04, 2024 |  |

5 of 5 investments shown.

## Co-investors
- [The TSC Alliance Endowment Fund](https://shizune.co/investors/profile/the-tsc-alliance-endowment-fund) — VC Fund, 3 deals together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 2 deals together
- [Regeneron Ventures](https://shizune.co/investors/profile/regeneron-ventures) — VC Fund, 2 deals together
- [Sofinnova Investments](https://shizune.co/investors/profile/sofinnova-ventures) — VC Fund, 2 deals together
- [Apollo Health Ventures](https://shizune.co/investors/profile/apollo-health-ventures) — VC Fund, 1 deal together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Life Science VC Funds in Belgium](https://shizune.co/investors/life-science-vc-funds-belgium)

## FAQ

### What does Luma Group invest in?

Luma Group invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Luma Group's check size?

Luma Group typically joins rounds of $40M–$125M at Series A and $55M–$93M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Luma Group participates in.

### How do I contact Luma Group?

Public channels for Luma Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Luma Group?

The team at Luma Group includes Themasap Khan (Co-Founder and Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co